Biohaven Acquires Rights for BHV-8000 to Treat Immune-Mediated Brain Disorders
Shots:
- Highlightll will receive $10M up front in cash, $10M in BHVN equity & ~$950M in development & commercial milestones along with royalty. Both companies will coordinate the clinical development across global regions
- Biohaven obtains global rights (Ex-China) for the development of BHV-8000, a highly selective, brain-penetrant, dual TYK2/JAK1 inhibitor to treat brain disorders
- Biohaven continues to advance BHV-8000 (previously TLL-041) licensed from Highlightll into a P-I study in 2023. In comparison to less selective or non-selective JAK inhibitors, BHV-8000 has been shown to have high selectivity over JAK2, JAK3, & other kinases potentially providing improved safety. In preclinical models, mechanistic PoC for BHV-8000 has been established
Ref: PR Newswire | Image: Biohaven
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
